Arena Pharma (ARNA) Announces Cost-Reduction Program; Will Trim U.S. Headcount by 35%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Arena Pharmaceuticals Announces New Strategic Focus and Cost Reduction Plan
October 27, 2015 4:00 PM EDTSAN DIEGO, Oct. 27, 2015 /PRNewswire/ --Â Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities.
Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on:
advancing its APD334 program, including the ongoing Phase 2 clinical trial for ulcerative colitis, and potentially exploring additional indications beyond inflammatory bowel disease through small pilot studies; advancing its ralinepag (formerly known as APD811) program, including its ongoing Phase 2 clinical trial... More